Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT

Blood

Volumn 98, Issue 4, 2001, Pages 972-978

  Van Esser, Joost W J ^a,b,c,d   Van Der Holt, Bronno ^a,b,c,d   Meijer, Ellen ^a,b,c,d   Niesters, Hubert G M ^a,b,c,d   Trenschel, Rudolf ^a,b,c,d   Thijsen, Steven F T ^a,b,c,d   Van Loon, Anton M ^a,b,c,d   Frassoni, Francesco ^a,b,c,d   Bacigalupo, Andrea ^a,b,c,d   Schaefer, Ulrich W ^a,b,c,d   Osterhaus, Albert D M E ^a,b,c,d   Gratama, Jan Willem ^a,b,c,d   Löwenberg, Bob ^a,b,c,d   Verdonck, Leo F ^a,b,c,d   Cornelissen, Jan J ^a,b,c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; THYMOCYTE ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VIRUS REACTIVATION;

EID: 0035883085     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.972     Document Type: Article

References (64)

1. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234-1243.
2. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520-529.
3. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B-cell lymphoproliferation. Transplantation. 1985;39:461-472.
4. Gross TG, Steinbusch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251-258.
5. Micallef INM, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant. 1998;22:981-987.
6. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
7. Hale G, Waldmann H for CAMPATH Users. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood. 1998;91:3079-3080.
8. Walker RC, Marshall WF, Strickler JG, et al. Pre-transplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346-1353.
9. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451-1456.
10. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders [letter]. Lancet. 1998;352:1285.
11. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11:S113-S116.
12. Kuehnle J, Huls MH, Lin Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
13. Papadopoulos E, Ladanyi M, Emmanuel D, et al. Infusions of donor lymphocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
14. Heslop HE, Ng CYC, Li C, et al. Long term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
15. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
16. Cavazzana-Calvo M, Bensoussan D, Jabado J, et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol. 1998;103:543-551.
17. McDiarmid SV, Jordan S, Lee GS, et al. Prevention and pre-emptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66:1604-1611.
18. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis. 1997;25:1344-1349.
19. Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation. 1995;59:135-138.
20. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807-814.
21. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant. 1995;9:53-59.
22. Trigg ME, Finlay JL, Sondel PM. Prophylactic acyclovir in patients receiving bone marrow transplants [letter]. N Engl J Med. 1986;26:1708-1709.
23. Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using pre-emptive antiviral therapy. Transplantation. 1997;64:848-852.
24. Green M, Reyes T, Jabbour N, et al. Use of quantitative PCR to predict onset of Epstein-Barr viral infection and post-transplant lymphoproliferative disease after intestinal transplantation in children. Transplant Proc. 1996;28:2759-2760.
25. Niesters HGM, Van Esser J, Fries E, et al. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol. 2000;38:712-715.
26. Van Esser JWJ, Niesters HGM, Thijsen SFT, et al. Molecular quantitation of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol. 2001;113:814-821.
27. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654-3661.
28. Savoie A, Perpête C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. 1994;83:2715-2722.
29. Beck R, Westdörp I, Jahn G, Schäfer H, Kanz L, Einsele H. Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow transplantation or peripheral blood stem cell transplantation [letter]. J Clin Microbiol. 1999;37:3430-3431.
30. Limaye AP, Huang M-L, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol. 1999;37:1113-1116.
31. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995;89:98-103.
32. Hoshino Y, Kimura H, Kuzushima K, et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load. Bone Marrow Transplant. 2000;26:199-201.
33. Rowe DT, Qu L, Reyes N, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol. 1997;35:1612-1615.
34. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leucocytes of patients with posttransplant lymphoproliferative disease. Transplantation. 1995;60:547-554.
35. Telenti A, Marshall WF, Smith TF. Detection of Epstein-Barr virus by polymerase chain reaction. J Clin Microbiol. 1990;28:2187-2190.
36. Yamamoto M, Kimura H, Hironaka T, et al. Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus associated diseases. J Clin Microbiol. 1995;33:1765-1768.
37. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132-136.
38. Riddler SA, Breinig MC, McKnight LC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 1994;84:972-984.
39. Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66:1641-1644.
40. Barkholt LM, Dahl H, Enbom N, Lindé A. Epstein-Barr virus DNA in serum after liver transplantation-surveillance of viral activity during treatment with different immunosuppressive agents. Transpl Int. 1996;9:439-445.
41. Lucas KG, Filo R, Heilman DK, Lee CH, Emmanuel DJ. Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients at risk for the development of lymphoproliferative disease [letter]. Blood. 1998;92:3977-3978.
42. Krieger NR, Martinez OM, Krams SM, Cox K, So S, Esquivel CO. Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients. Liver Transpl. 2000;6:62-66.
43. Baldanti F, Grossi P, Furione M, et al. High levels of Epstein-Barr virus DNA in blood of solid organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol. 2000;38:613-619.
44. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85:552-565.
45. Przepriorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-829.
46. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989;4:445-451.
47. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
48. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
49. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:187-220.
50. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A. 1988;85:8693-8696.
51. Gratama JW, Oosterveer MAP, Lepoutre JMM, et al. Serologic and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients. Transplantation. 1990;49:725-730.
52. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood. 1996;87:2594-2603.
53. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
54. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465-1470.
55. Ferrara JL. Cytokine inhibitors and graft-versus-host disease. Ann N Y Acad Sci. 1995;770:227236.
56. + T cells. J Immunol. 1995;155:2396-2406.
57. Hill GR, Crawford JM, Cooke JR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
58. Tosato G, Teruya-Feldstein J, Setsuda J, et al. Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Springer Semin Immunopathol. 1998;20:405-423.
59. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B-cells. J Virol. 1990;64:3033-3041.
60. Scala G, Quinto I, Ruocco MR, et al. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med. 1990;172:61-68.
61. Tosato G, Jones KD, Breinig MK, McWilliams HP, McKnight JLC. Interleukin-6 production in post-transplant lymphoproliferative disease. J Clin Invest. 1993;91:2806-2814.
62. Jones K, Rivera C, Sgadari C, et al. Infection of human endothelial cells with Epstein-Barr virus. J Exp Med. 1995;182:1213-1221.
63. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood. 2000;96:2814-2821.
64. Cornelissen JJ, Van Esser JWJ, Van Der Holt B, et al. Pre-emptive anti B-cell immunotherapy guided by quantitative PCR effectively reduces the incidence and mortality of Epstein-Barr virus lymphoproliferative disease (LPD) after allogeneic T-cell-depleted (TCD) stem cell transplantation (SCT) [abstract]. Blood. 2000;96:507a.